Gilead Sciences, Inc. (GILD) Stock Analysis

Gilead Sciences, Inc. (GILD) Stock Analysis — AI Research | MarketCI

GILD

Market Closed

Gilead Sciences, Inc.

NASDAQHealthcare Drug Manufacturers - General

17.60K employees

CEO: Daniel O'Day

Founded: 1992

$123.76

+$0.00(+NaN%)

Market Cap

153.66B

Beta

0.33

52W Range

N/A

Dividend Yield

2.60%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

GILD Price Chart

Historical price performance

Loading MCI price data...

MarketCI Investment Signals

AI-synthesized investment signal for GILD built from valuation, fundamentals, sentiment, and risk models

Investment Signal

Buy

Pass %

85.71%

Score

6/7

Fair Value Estimate

Cash flow analysis • Multiple methods

$174.22

AI Price Target

Machine learning • Price prediction

$124.86

Market Sentiment

News & social media analysis

0.12

Value Investor Price

Classic value analysis

$26.33

Financial Health

Bankruptcy risk assessment

4.70

Quality Score

Financial strength rating

9.00

AI Investment Grade

Deep analysis of filings & news

72.00

Key Investment Highlights

Important factors affecting GILD investment thesis

Due Diligence Analysis

Investment criteria assessment and scoring

Overall Assessment

76.74% Excellent

Conditions Met

33.00/43.00

Due Diligence Score

76.74%

Due Diligence Conditions

Investment analysis conditions and results


	Pass
	Pass
	Pass
	Pass
	Pass
	Pass

Showing 1 to 6 of 46 conditions